Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Otonomy Inc (OTIC)

2.63   0.04 (1.54%) 03-05 09:18
Open: 2.58 Pre. Close: 2.59
High: 2.69 Low: 2.42
Volume: 1,415,295 Market Cap: 127M
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.692 - 2.711 2.711 - 2.726
Low: 2.387 - 2.406 2.406 - 2.42
Close: 2.604 - 2.635 2.635 - 2.659

Technical analysis

as of: 2021-03-05 8:50:45 AM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.22     One year: 6.69
Support: Support1: 2.42    Support2: 2.01
Resistance: Resistance1: 4.47    Resistance2: 5.73
Pivot: 3.85
Moving Average: MA(5): 2.78     MA(20): 4.24
MA(100): 4.63     MA(250): 3.72
MACD: MACD(12,26): -0.67     Signal(9): -0.49
Stochastic oscillator: %K(14,3): 6.61     %D(3): 8.51
RSI: RSI(14): 26.82
52-week: High: 6.98  Low: 1.53  Change(%): -17.6
Average Vol(K): 3-Month: 118042  10-Days: 337818

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
OTIC has closed above bottom band by 25.2%. Bollinger Bands are 204.1% wider than normal. The large width of the bands suggest high volatility as compared to OTIC's normal range. The bands have been in this wide range for 8 bars. This is a sign that the current trend might continue.

Headline News

Fri, 26 Feb 2021
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock? - Nasdaq

Wed, 24 Feb 2021
Otonomy Inc. (OTIC) Soars 2.08% on February 24 - Equities.com

Wed, 24 Feb 2021
What is the Market's View on Otonomy Inc (OTIC) Stock's Price and Volume Trends Wednesday? - InvestorsObserver

Mon, 22 Feb 2021
ROCE Insights For Otonomy - Benzinga

Mon, 22 Feb 2021
Otonomy Inc (OTIC) Down 52.50% in Premarket Trading - InvestorsObserver

Mon, 22 Feb 2021
Otonomy stock loses half its value after disappointing trial results of vertigo treatment - MarketWatch

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 48
Shares Float (M) 38
% Held by Insiders 0.25
% Held by Institutions 77.21
Shares Short (K) 1,140
Shares Short P. Month (K) 1,110

Stock Financials

EPS -1.270
EPS Est This Year -3.230
EPS Est Next Year -2.310
Book Value (p.s.) 1.560
Profit Margin
Operating Margin -14070.93
Return on Assets (ttm) -26.5
Return on Equity (ttm) -71.6
Qtrly Rev. Growth -60.0
Gross Profit (p.s.) -0.006
Sales Per Share 0.006
EBITDA (p.s.) -0.889
Qtrly Earnings Growth
Operating Cash Flow (M) -38
Levered Free Cash Flow (M) -22

Stock Valuations

PE Ratio -2.07
PEG Ratio
Price to Book value 1.69
Price to Sales 405.26
Price to Cash Flow -3.35

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.